期刊文献+

表皮生长因子受体在结直肠癌的表达及临床病理意义 被引量:2

Expression of Epidermal Growth Factor Receptor in Colorectal Carcinomas and its Clinicopathological Significance
下载PDF
导出
摘要 目的探讨表皮生长因子受体(EGFR)在结直肠癌中的表达情况及其与病理特征和预后的关系。方法采用免疫组化SP法对有随访资料的55例结直肠癌标本进行EGFR检测,结合图像分析观察判定结果。结果结直肠癌EGFR表达的阳性率为69.09%(38/55),EGFR的表达与肿瘤的浸润深度、淋巴结转移、Duke's分期和生存期有关(P均<0.05),而与分化程度无关(P>0.05)。结论EGFR在结直肠癌的扩散和转移过程中可能产生一定的作用。 Objective\ To study the expression of epidermal growth factor receptor(EGFR) in colorectal carcinomas, and its clincal and pathological significance.\ Methods\ EGFR was determined immunohistochemically in 55 specimens of colorectal carcinomas which had been followed up regularly. \ The results were observed and judged through image analysis.\ Results The positive rate of EGFR in colorectal carcinomas was 69.09%(38/55). \ The expression of EGFR was concerned with infiltrative depth,lymphatic metastasis、Duke's stage and survival period of tumour(P<0.05 respectively),but was irrelative to differential degrees(P>0.05).\ Conclusion\ EGFR might play a definite role in the process of diffusion and metastasis of colorectal carcinomas, and be used as an important index for the assessment of prognosis.
机构地区 福建医科大学
出处 《福建医科大学学报》 1999年第1期31-34,共4页 Journal of Fujian Medical University
基金 福建省卫生厅科研基金
关键词 结肠直肠癌 病理 表皮生长因子 受体 epidermal growth factor receptor colorectal carcinomas immunohistochemistry
  • 相关文献

参考文献4

二级参考文献5

共引文献17

同被引文献13

  • 1姚根有,阮俊,赵仲生,胡云琴.细胞周期素E和表皮生长因子受体在乳腺癌中的表达及与预后的关系[J].中华普通外科杂志,2004,19(8):483-485. 被引量:4
  • 2Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decay receptor for Fas ligand in lung and colon cancer [J]. Nature,1998,396(6712):699-703.
  • 3Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DCR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster [J]. Proc Natl Acad Sei USA, 2000,97(3):1230-1235.
  • 4Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6)suppresses light-mediated apoptosis [J]. J Biol Chem,1999,274(20):13733-13736.
  • 5Victor J, Witcher DR, Becker GW, et al. Decoy receptor 3 (DCR3) is proteolytically processed to a metabolic fragment hawing differential activities against Fas ligand and light [J]. Biochem Pharmacol,2003,65:657- 667.
  • 6Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. Clin Oncol,2003,21 (14):2787-2799.
  • 7Jose B. Why the epidermal growth factor receptor? The rational for cancer therapy [J]. Oncologist,2002,(Supp 4):2-8.
  • 8Connolly K, Cho YH, Duan R, et al. In vivo inhibition of Fas ligand- mediated killing by TR6, a Fas ligand decoy receptor [J]. J Pharmacol Exp Ther,2001,298(1):25-33.
  • 9F.Graziano, F. Arduini, A. Ruzzo, et al. Combined analysis of E-cadherin gene(CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs[J]. Annals of oncology, 2004, 15(3): 489-492.
  • 10孙红,刘小平,李明众,南克俊.上皮型钙黏蛋白在宫颈癌中的表达及其临床意义[J].中华肿瘤杂志,2000,22(6):496-498. 被引量:5

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部